Managing Adverse Effects From Oral Kinase Inhibitors in Patients With Hematologic Cancers
Ibrutinib, idelalisib, ponatinib, and ruxolitinib are each associated with a variety of potential adverse effects and oncology nurses must be aware of these to successfully monitor for them.
